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S U M M A R Y
Mycobacterium septicum is a rapidly growing Mycobacterium (RGM) that rarely causes pulmonary
disease globally. We describe a case of M. septicum pulmonary disease, which to our knowledge is the
ﬁrst reported in China. The isolates were identiﬁed as M. septicum and were susceptible in vitro to
amikacin, ciproﬂoxacin, oﬂoxacin, levoﬂoxacin, kanamycin, and sulfamethoxazole.
 2013 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Mycobacterium septicum is a rapidly growing non-tuberculous
Mycobacterium (NTM), and has been identiﬁed phenotypically as a
member of the Mycobacterium fortuitum third biovariant com-
plex.1,2 There are a few reports of M. septicum infections, but cases
of pulmonary disease caused by M. septicum are rare. To our
knowledge, no other case of M. septicum infection has been
reported in China thus far. We report herein a case of M. septicum
infection in a patient suffering from pulmonary disease.
2. Case report
A 42-year-old man was admitted to the local hospital with a 3-
month history of cough and weight loss of 10 kg on August 17,
2010. Before admission, the patient had visited the local clinic and
had been treated with anti-inﬂammatories and cough medicine;
however his condition failed to improve.
A chest computed tomography image showed ﬁbrous cavern-
ous shadows of irregular size and shape in the lung apex bilaterally
and in the inferior lingular segment of the left lung. The largest
shadow was 6.1 cm  4.5 cm; multiple nodule shadows with
diameters of about 0.2–0.5 cm were irregularly distributed
throughout the lungs bilaterally. Their boundaries were obscure,* Corresponding author. Tel.:/fax: +86 10 58900779.
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along with lymph node shadows in the mediastinum. The
diagnostic impression was chronic ﬁbro-cavitary pulmonary
tuberculosis with bilateral lung dissemination. On August 18,
2010, the patient was referred to the local institute for tuberculosis
control and prevention. On August 18 and 20, 2010, bacteriological
examinations showed that a sputum smear and culture test were
positive for acid-fast bacilli (AFB). He was diagnosed in the local
institute with chronic ﬁbro-cavitary pulmonary tuberculosis with
bilateral lung hematogenous dissemination II. In August 2010, a 2-
month intensive phase and a 4-month continuous phase
(2H3R3Z3E3/4H3R3. H: isoniazid, R: rifampicin, Z: pyrazinamide,
E: ethambutol) were initiated as therapeutic regimens under full-
course supervision and management, adding levoﬂoxacin for 1
month. On October 12, 2010 and January 13 and February 14, 2011,
sputum smears for AFB were negative. The patient’s condition
improved and the treatments were stopped on February 16, 2011.
Unfortunately he relapsed in March 2012, and sputum smear and
cultures again tested positive for AFB. The strain, numbered
SC11091, was stored and identiﬁed at the National Tuberculosis
Reference Laboratory (NTRL), National Institute for Communicable
Disease Control and Prevention (ICDC), Chinese Center for Disease
Control and Prevention (China CDC).
Antimicrobial susceptibility tests3,4 were performed using a
microplate Alamar blue assay (AbD Serotec, USA) (MBA)5,6 and
Etest (bioMe´rieux, Solna, Sweden).4 The control group was M.
septicum reference strain DSM 44393. Table 1 shows that SC11091,
similar to the reference strain, was resistant to mostternational Society for Infectious Diseases.
Table 1
Minimum inhibitory concentrations (MICs) of drug sensitivity test on Mycobacterium septicum DSMZ 44393 and SC11091
No. Drugs Intermediate M. septicum DSMZ 44393 SC11091
Etest8 MBA1,6,7 Etest MBA Etest MBA
1 Rifampin 1–4 0.1 32 (+) 64 (+) 32 (+) 64 (+)
2 Isoniazid a 1 a >256 (+) a >256 (+)
3 Streptomycin 1 5 16 () 16 (+) 32 () 32 (+)
4 Ethambutol 0.064–0.25 1 0.75 (+) 8 (+) 6 (+) >256 (+)
5 Amikacin 16–64 16–64 0.38 () 0.5 () 0.5 () 4 ()
6 Ciproﬂoxacin 16–128 1–4 0.023 () 0.25 () 0.032 () 0.25 ()
7 Oﬂoxacin 2–8 2–8 0.125 () 0.5 () 0.094 () 0.5 ()
8 Kanamycin 16–64 16–64 1.5 () 4 () 3 () 4 ()
9 Ethionamide 0.016–0.064 0.016–0.064 256 (+) >256 (+) 256 (+) >256 (+)
10 Linezolid 8–32 8–32 1.0 () 2 () 8 () 8 ()
11 Azithromycin 2–8 a 6 () a 48 (+) a
12 Clarithromycin 2–8 a 3 () a 256 (+) a
13 Imipenem 4–16 a 1 () a 3 () a
14 Quinupristin 1–4 a 32 (+) a 32 (+) a
15 Tigecycline 1–2 a 0.064 () a 0.064 () a
16 Capreomycin a b a 2 a 2
17 p-Aminosalicylic acid a b a >256 a >256
18 Dipasic a b a >256 a >256
19 Tetracycline a b a 8 a >128
20 Doxycycline a 16 a 16 (+) a >256 (+)
21 Sulfamethoxazole a 32 a >256 (+) a 16 ()
22 Minocycline a 16 a 8 () a >256 (+)
23 Cefoxitin a 16–128 a 16 (+) a >256 (+)
24 Levoﬂoxacin a 2–8 a 0.25 () a 0.125 ()
MBA, microplate Alamar blue assay; (+), resistant; (), susceptible.
a No intermediate was available.
b No test under the item.
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rifampin, streptomycin, and ethambutol; however it was suscep-
tible in vitro to amikacin, ciproﬂoxacin, oﬂoxacin, levoﬂoxacin,
kanamycin, and sulfamethoxazole.
The isolates that were positive for AFB were proven to be NTM
using the improved Lowenstein–Jensen medium, para-nitro-
benzoic acid (PNB) and thiophene-2-hydrazine carboxylic acid
(TCH) media, and multilocus PCR.7 The sequences of the gene
hsp658,9/rpoB10 were sent to the BLAST online database for
sequence alignment and were found to be similar to M. septicumFigure 1. The phylogenetic consensus tree based on hsp65 sequences illustrating the pos
using Mycobacterium tuberculosis H37Rv as the out-group. Scale bar, 1% difference in tstrain ATCC 700731, achieving a 99% match. Using MEGA version
5.01 software package, the phylogenetic consensus tree based on
hsp65 sequences illustrated the position of the strain SC11091,
which was nearest to M. septicum strain ATCC 700731 and DSM
44393 (Figure 1).
3. Discussion
The patient was admitted to the local hospital with a persistent
cough, and sputum samples were isolated and found to beition of SC11091 and some reference strains of Mycobacterium. The tree was rooted
he sequences.
L. Lian et al. / International Journal of Infectious Diseases 17 (2013) e352–e354e354AFB-positive on culture. Combining clinical and bacteriologic
examinations with molecular biological identiﬁcation results, the
patient was ﬁnally diagnosed with pulmonary disease caused by
M. septicum, as the clinical manifestations were similar to those of
pulmonary diseases caused by M. tuberculosis. As usual, it was
difﬁcult to distinguish pulmonary disease caused by NTM from
that caused by M. tuberculosis, because they have the same
symptoms and AFB results. This confusion often leads to
misdiagnosis, resulting in a series of mistakes, e.g., inadequate
treatment regime, delayed healing of diseases, relapses, and the
generation of multidrug-resistant (MDR) or extensively drug-
resistant (XDR) mycobacteria.
Though the patient improved after using the therapeutic
regimens 2H3R3Z3E3/4H3R3 under full-course supervision and
management and the addition of levoﬂoxacin for 1 month, he
relapsed within 1 year of stopping the treatment. Sputum smear
and culture tests were also positive for AFB. There are several
reasons for a discussion of this case. First, in China, although
patients with tuberculosis receive treatment either at the local
tuberculosis institute or at hospitals, it might not be effective for
them. Second, there is no effective treatment program for NTM
diseases in the world, because most NTM, as opportunistic
pathogens, display multidrug resistance to anti-tuberculosis drugs
in nature. Third, minimum inhibitory concentrations (MICs) for the
isolate showed that the pathogen was susceptible to levoﬂoxacin;
however this modiﬁcation led to treatment failure or relapse.11
Also, the American Thoracic Society (ATS) has stated that
susceptibility testing of clinically signiﬁcant rapidly growing
mycobacteria (RGM; e.g., M. fortuitum, M. abscessus, and M.
chelonae) should not be performed with anti-tuberculosis agents.12
Therefore, further investigations are necessary.
Since 2000, M. septicum has been identiﬁed, named,2 and
described as the cause of various human infections. There have
been several reports of M. septicum infection in other parts of the
body, while pulmonary disease has rarely been reported world-
wide. M. septicum is an opportunistic pathogen, similar to many
other NTM species. In 2000, the organism was reported to be one
species of the M. fortuitum complex, and known as the unnamed
third biovariant complex.13 Species belonging to the M. fortuitum
group are a relatively rare cause of disseminated mycobacterial
pulmonary disease.11 Further, most of the isolates that have been
studied have been environmental strains and none have had a
deﬁnite disease association.11 Here, we have described a case of
pulmonary disease caused by M. septicum, which is the ﬁrst report
in China. The isolates were identiﬁed using both conventional
microbiological methods and hsp65 and rpoB gene sequence
analysis. Further, the phylogenetic consensus tree based on hsp65
sequences shows that the sequence of SC11091 is closer to that of
M. septicum strain ATCC 700731 and DSM 44393.
Our ﬁndings show that M. septicum, despite being rare, is
capable of causing pulmonary disease. Furthermore, in the clinical
and laboratory diagnosis of rare NTM infectious disease, NTMspecies should be isolated and identiﬁed in order to avoid delays in
the diagnosis and treatment and to prevent failure or relapse.
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